Final Programme. 11t h European Peritoneal Dialysis Meeting th - 14th October 2013 MECC, Maastricht, The Netherlands

Transcription

1 11-14 October 2013 Maastricht, The Netherlands Putting Patients in the Driving Seat 11t h European Peritoneal Dialysis Meeting th - 14th October 2013 MECC, Maastricht, The Netherlands Final Programme In association with:

2 Want to find out what happened to the right flower? Come and visit us at our booth at the EuroPD Fresenius Medical Care Deutschland GmbH Bad Homburg Germany

3 11-14 October 2013 Maastricht, The Netherlands CONTENTS Scientific Programme...2 Additional Information...17 Exhibitors and Sponsors...20 MECC Centre Plans...23 Platinum Sponsors EuroPD greatly appreciate the support of the following companies: Meeting Organisers EuroPD 2011, c/o In Conference Ltd, Unit 1, Q Court, Quality Street, Edinburgh EH4 5BP, UK Tel: +44(0) Fax: +44(0) europd@in-conference.org.uk Web: Scientific Programme Committee Nick Topley, President, EuroPD, Cardiff, UK Wim Van Biesen, Chair, Scientific Programme, Ghent, Belgium Simon Davies, Stoke-on-Trent, UK Achim Jörres, Berlin, Germany Janusz Witowski, Poznan, Poland Local Organising Committee Karel Leunissen, Maastricht - Joint President Jurgen Floege, Aachen - Joint President Tom Cornelis, Maastricht Bart De Moor, Hasselt Eric Goffin, Brussels Jeroen Kooman, Maastricht George Schlieper, Aachen Frank van der Sande, Maastricht 1

4 EuroPD 2013 Final Programme Pre-Conference Programme (only open to delegates who have pre-registered for these courses) Friday 11 th October Registration Open Trajectum Foyer Speaker Preview Open Room 0.6 / Madrid Tea / Coffee for Pre-Conference Course Delegates only Level 0 Lobby Pre-Conference Educational Course A: Basic Track Chairs: T Cornelis, Maastricht, The Netherlands, B De Moor, Hasselt, Belgium Room 0.4 / Brussels Basic PD Physiology B Bammens, Leuven, Belgium Basic PD Prescription S Davies, Stoke on Trent, UK Modality Selection J Perl, Toronto, Canada When to Start Dialysis? N Lameire, Ghent, Belgium Lunch Level 0 Lobby Peritoneal Catheter Implantation Techniques A Slingeneyer, Montpellier, France When to use which PD Solution E Goffin, Brussels, Belgium Volume Management G Woodrow, Leeds, UK Management of Infectious Complications E Brown, London, UK Room 0.4 / Brussels 2

5 11-14 October 2013 Maastricht, The Netherlands Friday 11th October cont Pre-Conference Educational Course B: Advanced Track Chairs: J Kooman, Maastricht, The Netherlands, G Schlieper Aachen, Germany Room 0.5 / Paris Cardiovascular work up for Transplantation J Pascual, Barcelona, Spain Non PD Related Issues that Influence the PD Membrane A Pletinck, Ghent, Belgium New Insights in Uremic Toxins and the Need for Alternative Dialysis Techniques W Van Biesen, Ghent, Belgium Cardiovascular Disease: Better PD or HD? M Kimmel, Stuttgart, Germany Lunch Level 0 Lobby Biocompatibility: An Update from the Bench A Jorres, Berlin, Germany Biocompatibility: An Update from the Bedside D Johnson, Brisbane, Australia Advanced Approach to Peritoneal Membrane Testing (ERBP View) O Heimbürger, Stockholm, Sweden Diabetes and Peritoneal Dialysis J Heaf, Herlev, Denmark Home HD: A Start to HHD Primer S Mitra, Manchester, UK Room 0.5 / Paris 3

6 EuroPD 2013 Final Programme Friday 11th October 2013 Main Conference Registration Open Trajectum Foyer Speaker Preview Open Welcome & Opening Plenary Entertainment provided by Vlaams Koperkwartet Welcome Welcome from the President of EuroPD and Chairs of the Local Organising Committee N Topley, President, EuroPD Musical Interlude Home Based Therapy for the Homeless: The Dolphin Man M Silke, Galway University Hospital Musical Interlude Challenges and Opportunities in CKD Care in the Future K Leunissen, Maastricht, The Netherlands Room 0.6 / Madrid Auditorium I th EuroPD Welcome Reception Opening of the Exhibition, Posters and Reception Expo Hall Buffet & Refreshments will be provided 4

7 11-14 October 2013 Maastricht, The Netherlands Saturday 12th October Registration and Speaker Preview Open Exhibition and Posters Open Masterclasses: Session A (Parallel Sessions) A1 - How to Place a PD Catheter N Peppelenbosch, Maastricht, The Netherlands A2 - How to Manage Ultrafiltration S Fan, London, UK A3 - How to Manage Glucose Control in ESRD Patients J Heaf, Herlev, Denmark Trajectum Foyer & Room 0.6/ Madrid Expo Hall Room 0.4 / Brussels Room 0.5 / Paris Room 0.2 & 0.3 / Copenhagen Infection Chairs: A Ekstrand, Helsinki, Finland & P ter Wee, Amsterdam, The Netherlands Infection, Immunity and Inflammation in PD M Eberl, Cardiff, UK What do we Learn from Pharmacology and Microbiology D Vogelaers, Ghent, Belgium Vancomycin in Peritoneal Dialysis: Evidence and Uncertainties A De Vriese, Brussels, Belgium Tea / Coffee / Exhibition / Posters Expo Hall Parallel Session 1: Clinical Cases on Volume Management Chairs: W van Biesen, Ghent, Belgium, G M Gahl, Berlin, Germany Case 1 - Ultrafiltration Failure O Heimbürger, Stockholm, Sweden Free Communications O1 Frail and Elderly Patient Outcomes on Dialysis (FEPOD): A Two Part Study E Brown, Hammersmith Hospital, London, UK 5

8 EuroPD 2013 Final Programme Saturday 12th October cont Free Communications O2 How does Knowing Bioimpedance Measurements Influence Fluid Management in PD? Results from the UK-Shanghai Randomised Control Trial B K Tan, University Hospital of North Staffordshire & Keele University, Stoke on Trent, UK Case 2 - A Difficult Case of Ultrafiltration Failure J P Kooman, Maastricht, The Netherlands Parallel Session 2: Anticoagulation in CKD5 Patients Chairs: N Lameire, Ghent, Belgium PD: A Prothrombotic State? N Lameire, Ghent, Belgium Anticoagulation in Advanced CKD: What Nephrologists Should Know D Frank, Eschweiler, Germany Vitamin K and Coumarines in CKD 4-5 G Schlieper, Aachen, Germany Anticoagulation During Home and Extended HD: How is it Different from Conventional Centre HD? A Dhondt, Ghent, Belgium Auditorium Lunch / Exhibition / Posters (Poster Session 1 Odd Numbers) Expo Hall Industry Symposium I Importance of Choosing the Right PD Fluids: Conclusive Evidence Chairs: S Davies, Stoke-on-Trent, UK, & W Van Biesen, Ghent, Belgium Does the Use of Neutral ph, Low Glucose Degradation Product Peritoneal Dialysis Fluids Lead to Better Patient Outcomes? D Johnson, Brisbane, Australia 6

9 11-14 October 2013 Maastricht, The Netherlands Saturday 12th October cont Does Biocompatibility Matter for Volume Control? M Fischbach, Strasbourg, France Lessons from the IPOD Study on the Impact of Biocompatible PD Fluids in Clinical Practice Reality: Preliminary Results W Van Biesen, Ghent, Belgium Parallel Session 3: How to...series Chair: D Johnson, Brisbane, Australia How to Set Up and Run a Clinical Trial D Johnson, Brisbane, Australia How to Obtain the Evidence from Published Research? E Nagler, Ghent, Belgium How to do Proper Statistics M van Diepen, Leiden, The Netherlands Parallel Session 4: How to Optimise Quality of Life? Chairs: E Brown, London, UK & M Dratwa, Brussels, Belgium How to Measure Quality of Life E Boeschoten, Huizen, The Netherlands How to Improve Quality of Life Practical Issues M Lichodziejewska-Niemierko, Gdansk, Poland Conservative and End of Life Care: A Dead End Street? E Brown, London, UK Happy Team, Happy Patient: Understanding the Impact of Personal Emotions on the Caregiver-Patient Relationship D Benoit, Ghent, Belgium Auditorium Discussion Tea / Coffee / Exhibition / Posters Expo Hall A Critical Overview of the Literature Chairs: J Witowski, Poznan, Poland & M Wilkie, Sheffield, UK Clinical PD A Critical Review of the Literature M Wilkie, Sheffield, UK Basic Science: Peritoneal Membrane J Witowski, Poznan, Poland 7

10 EuroPD 2013 Final Programme Saturday 12th October cont Parallel Session 5: Congestive Heart Failure Chairs: J P Kooman, Maastricht, The Netherlands & M Wilkie, Sheffield, UK Pathophysiological Approach to Congestive Heart Failure H Peter Brunner-La Rocca, Maastricht, The Netherlands Congestive Heart Failure: Should the Nephrologist Take it to Heart? B Maes, Roeselare, Belgium Parallel Session 6: Posters Selected for Discussion Chairs: K Donovan, Cardiff, UK & J Witowski, Poznan, Poland Auditorium 2 Expert Panel: D Johnson, Brisbane, Australia & P ter Wee, Amsterdam, The Netherlands P27 - Development of a United Kingdom Peritoneal Dialysis Access Audit Initial Results and Future Considerations P40 - No Differences in Overnight Sodium Removal between Automated Peritoneal Dialysis using Standard and Tidal Prescription P56 - The Relationships between the Glucose Load and Inflammation in Peritoneal Dialysis Patients P65 - Increased Dialysate Glucose adversely affects Systemic Glucose Metabolism in Non-diabetic PD Patients: Results from the GLOBAL Fluid Study P66 - Competing Risks of Encapsulating Peritoneal Sclerosis and Death in Peritoneal Dialysis: Results From PD-CRAFT P69 - Beliefs and Practices- A Survey of Health Care Professionals managing CKD and RRT in England P141 - The Mutual Relationship between Peritonitis and Peritoneal Transport P147 - Systemic Microvascular Endothelial Glycocalyx and Peritoneal Transport in PD Patients P148 - The Peritoneal Endothelial Glycocalyx in Uremic Rats The Effect of Dialysis Solutions and Relationships with Peritoneal Transport 8

11 11-14 October 2013 Maastricht, The Netherlands Sunday13th October Registration and Speaker Preview Open Trajectum Foyer & Room 0.6 / Madrid Exhibition and Posters Open Expo Hall Masterclasses: Session B (Parallel Sessions) B1 - How to do Exit Care M Lichodziejewska-Niemierko, Gdansk, Poland B2 - How to Achieve Adequate Small Solute Clearance W Van Biesen, Ghent, Belgium B3 - Management of Glucose Lowering Therapy in ESRD P ter Wee, Amsterdam, The Netherlands Room 0.4 / Brussels Room 0.5 / Paris Room 0.2 & 0.3 / Copenhagen The Membrane: Applied Current Understanding of Peritoneal Membrane Biology: A Pro - Con Debate Chairs: J Floege, Aachen, Germany & S Davies, Stoke on Trent, UK Applied Current Understanding of Peritoneal Membrane Biology J Floege, Aachen, Germany EMT is an Important Concept :Its Diagnostic and Therapeutic Value M López Cabrera, Madrid, Spain Fibrosis and EMT are no Promoters of Damage Progression to ESRD W Kriz, Mannheim, Germany Discussion Applied Current Understanding of Membrane Physiology: A Pro - Con Debate S Davies, Stoke on Trent, UK It s All About Streaming Potentials M Moeller, Aachen, Germany It s All About Pores B Rippe, Lund, Sweden Discussion 9

12 EuroPD 2013 Final Programme Sunday 13th October cont Tea / Coffee / Exhibition / Posters Expo Hall Parallel Session 7: Younger and Older EuTRiPD Auditorium 2 Bridging the Generation Gap in PD Research Chairs: R Beelen, Amsterdam, The Netherlands and C Aufricht, Vienna, Austria Introduction to EuTRiPD R Beelen, Amsterdam, The Netherlands Training in EuTRiPD C Aufricht, Vienna, Austria The Impact of Dialysis Fluids on Senescent Mesothelial Cells A Rudolf, Poznan, Poland Functional Characterization of Peritoneal Fibroblasts and the Understanding of their role in Peritoneal Immunity and PD E Kawka, Berlin, Germany Application of 2D-DIGE and Saturation Cyanine dyes in the Evaluation of Peritoneal Dialysis induced Oxidative Stress S Tarantino, Vienna, Austria Pathogen-specific Microbial sensing in Early Infection: Implications for Diagnosis and Therapy of Peritoneal Dialysis Patients A R Liuzzi, Cardiff, UK Inhibition of GSK-3β to Protect Primary Mesothelial Cells during in-vitro PD K Bialas, Vienna, Austria TH17 / Treg balance as Switch Point in Peritoneal Fibrosis Pathway G Liappas, Madrid, Spain Peritoneal Dialysis follow-up by Imaging I Calm Vidal, Strasbourg, France 10

13 11-14 October 2013 Maastricht, The Netherlands Sunday 13th October cont Anti-inflammatory Interventions in a Rat PD Model E Ferrantelli, Amsterdam, The Netherlands Auditorium Defining Current and Future needs of Peritoneal Dialysis (PD) Patients: Translation of Research into Peritoneal Dialysis Fluid Development A Machowska, Braine L Alleud, Belgium Evaluation of Mesothelial Cell microrna Profile in an in vitro Model of Peritoneal Fibrosis M Lopez Anton, Cardiff, UK Time Dependent changes of the Peritoneal Membrane in Health and Biocompatible PD M Bartosova, Heidelberg, Germany Parallel Session 8: Clinical Practice Track - What Do Patients Want Chairs: W van Biesen, Ghent, Belgium & B Maes, Roeselare, Belgium The CEAPIR Data on Patient s Perception of Dialysis M Murphy, Dublin, Ireland Listening to the Patient H Hurst, Cheshire, UK Guidelines and Shared Decision Making: Tips and Pitfalls S Treweek, Aberdeen, UK A Pro - Con Debate Will Patients Using Decision Aids to Make Dialysis Treatment Choices be Happier Patients? Pro - Will Patients using Decision Aids to make Dialysis Treatment Choices be Happier? H Bekker, Leeds, UK Con Speaker TBC Debate Lunch / Exhibition / Posters (Poster Session 2 Even Numbers) Expo Hall 11

14 EuroPD 2013 Final Programme Sunday 13th October cont Industry Symposium II Driving Improvements in Patient Outcomes Chair: S Konings, Eindhoven, The Netherlands Welcome and Introduction S Konings, Eindhoven, The Netherlands Mapping the Journey The Benefits of Starting with PD F van der Sande, Maastricht, The Netherlands What is the View from the Driver s Seat Really Like? P Kreilkamp, Munich, Germany Reducing Risk along the Way Prescribing PD Therapy M Amoedo, Evora, Portugal Driving Out of the City High Dose Home HD N Clyne, Lund, Sweden Q&A Session S Konings, Eindhoven, The Netherlands Summary and Conclusions Parallel Session 9: Enhance Personal Dialysis Prevalence Chairs: T Cornelis, Maastricht, The Netherlands, & E Goffin, Brussels, Belgium Preventing Patient Burn Out A S Rodrigues, Porto, Portugal Is there Really a Contra-Indication to PD E Goffin, Brussels, Belgium Factors Contributing to Successful Self Care Programme. An Example from Poland M Lichodziejewska-Niemierko, Gdansk, Poland 12

15 11-14 October 2013 Maastricht, The Netherlands Sunday 13th October cont Why do Self Care Progams Fail? F Locatelli, Lecco, Italy Can Technology be of Help to Support Personal Dialysis? C Ronco, Vicenza, Italy Parallel Session 10: Recent Progress in Peritoneal Dialysis: from Bench to Bedside Chairs: A Jorres, Berlin, Germany & J Witowski, Poznan, Poland Biocompatibility: Coming of Age? A Jörres, Berlin, Germany Biomarkers: Can they be a Surrogate Outcome Marker in Studies? J Witowski, Poznan, Poland Free Communications O3 Th17 Response as a Major Factor in Inflammation Induction and Fibrosis in CD69 -/- Mice during Peritoneal Dialysis G Liappas, Centro de Biología Molecular-Severo Ochoa-CSIC, Madrid, Spain Free Communications O4 AQP1-agonist AqF026 Modulates Water Transport during PD J Morelle, Université catholique de Louvain, Brussels, Belgium Auditorium Tea / Coffee / Exhibition / Posters Expo Hall Literature Update Chairs: D Fraser, Cardiff, UK & F van der Sande, Maastricht, The Netherlands Literature Update on Home Hemodialysis T Cornelis, Maastricht, The Netherlands Peritoneal Immunobiology D Fraser, Cardiff, UK 13

16 EuroPD 2013 Final Programme Sunday 13th October cont Free Communications O5 PD Membrane Transformation: Results from the International Pediatric Peritoneal Biopsy Study B Schaefer, University of Heidelberg, Germany Free Communications O6 A Novel Approach from Peritoneal Dialysis Access Evaluation: Post-implantation X-ray Parameters Predict Functional Catheter Problems B Bammens, University Hospitals Leuven, Belgium 14

17 11-14 October 2013 Maastricht, The Netherlands Monday 14 th October Registration and Speaker Preview Open Trajectum Foyer & Room 0.6 / Madrid Exhibition and Posters Open Masterclasses: Session C (Parallel Sessions) Expo Hall C1 - How to Revitalise A Non-Functioning Peritoneal Catheter A Slingeneyer, Montpellier, France C2 - How to Avoid Obesity and Malnutrition C Verger, Pontoise, France C3 - Classic Cardiovascular Prevention A S Rodrigues, Porto, Portugal Room 0.4 / Brussels Room 0.5 / Paris Room 0.2 & 0.3 / Copenhagen Comorbidities and Dialysis Chairs: K Donovan, Cardiff, UK & J Heaf, Copenhagen, Denmark Management of CKD-MBD in the PD Population P Evenepoel, Leuven, Belgium Iron Management in the Home Patient L Del Vechhio, Lecco, Italy Home Haemodialysis: Creative Solutions for the Elderly A Jayanti, Manchester, UK Tea / Coffee (Exhibition & Posters close at 10.30) Expo Hall Parallel Session 11: Clinical Session: Personalised Dialysis in a Globalised World Chairs: S Davies, Stoke on Trent, UK & N Lameire, Ghent, Belgium In association with ISPD 15

18 EuroPD 2013 Final Programme Monday 14th October cont Update on PDOPPS - Will a Global Understanding of How Practice Patterns Effect Patient Outcomes Lead to More or Less Personalised Dialysis? J Perl, Toronto, Canada Improving Knowledge of Juniors and Trainees on Personalised Dialysis: The Role of Universities, National Societies, EuroPD and ISPD S Davies, Stoke on Trent, UK Demographics and Pressure on Health Care Budgets: Send them all home? N Lameire, Ghent, Belgium Caring vs Curing. Changing Paradigm of Our Approach to Chronic Disease W van Biesen, Ghent, Belgium Parallel Session 12: Basic Science Session Chairs: J Floege, Aachen, Germany & J Witowski, Poznan, Poland Current Understanding of Cardiovascular Calcification in CKD and it s Implications for Therapy J Floege, Aachen, Germany Tools of Volume Status Evaluation J P Kooman, Maastricht, The Netherlands Cytoprotection: What do we Need to Know About it and What is its Role in PD C Aufricht, Vienna, Austria EPS: Our Current Understanding of Epidemiology, Pathophysiology and Management D Alscher, Stuttgart, Germany 0.4 Brussels / 0.5 Paris Prizes & Closing Remarks 16

19 11-14 October 2013 Maastricht, The Netherlands Additional Information Exhibition (Expo Foyer) Registration (Trajectum Foyer) Speaker Preview (Room 0.6 / Madrid) Friday 11 th October Saturday 12 th October Sunday 13 th October Monday 14 th October Accompanying Persons Please note that Accompanying Persons will not have access to the scientific sessions or teas/coffees or lunches. However they can attend the Welcome Reception, tickets cost 36 per person. An on-site booking facility will be available at the registration desks. Certificate of Attendance & CME Accreditation EuroPD 2013 has been awarded 20 CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). Those attending one of the Pre-Conference Courses will be awarded 3 credits and those attending the Main Conference 17 credits. Only those attending both sections of the meeting will be awarded the full 20 credits. Certificates of attendance will be sent electronically on the last day of the meeting. Accreditation certificates will be sent electronically on the individual s completion of the online questionnaire. Cloakroom There will be a cloakroom available free of charge. Please note that this area is not manned and therefore items are left at your own risk. Insurance The meeting cannot accept any liability for personal injuries or for loss or damage to property belonging to delegates, either during, or as a result of the meeting. Please check the validity of your own personal insurance before travelling. 17

20 EuroPD 2013 Final Programme Posters Poster presentations will be displayed throughout the conference. Authors will be by their boards at the following times: Poster Session I Saturday 12 th October Odd Numbered Posters (P1, P3 etc.) Poster Session II Sunday 13 th October Even Numbered Posters (P2, P4 etc.) Poster Themes Cardio-Vascular (Co-morbidity) Clinical PD Dialysis Solutions Infection Membrane Biology Membrane Function Paediatrics P1 P17 P18 P111 P112 P122 P123 P141 P142 P143 P144 P154 P155 P158 Photography, Filming & Mobile Phones Please note that filming and photography is absolutely prohibited in any of the scientific sessions. Mobile phones should be switched off or placed on silent during the scientific sessions. Thank you for your co-operation. Registered delegates Name badge must be worn If you are a fully registered delegate for the Meeting, the following is included: Attendance at the scientific sessions and entry to the exhibition Delegate bag and contents Name badge this should be worn at all times Attendance at the Welcome Reception on Friday 11 th October 2013 *Please note that Exhibitor Personnel will not have access to the scientific sessions 18

21 11-14 October 2013 Maastricht, The Netherlands Special Requirements If you notified the organisers of a special dietary requirement, excluding vegetarian, you will find the requirements printed on the back of your badge. There will be a dedicated catering point for you to collect your lunches, please ask at the EuroPD registration desk where this will be located. Travel Pass EuroPD is providing free travel for its delegates on local buses within Maastricht. Delegates need to present their badge to the driver to travel for free. Tweeting We welcome you to join the discussion at EuroPD 2013 on twitter. Please use #EuroPD2013 Wi-Fi There is complimentary Wi-Fi in all the public areas in the building. Please check the notice board at the registration desk for login details. 19

22 EuroPD 2013 Final Programme Exhibitors and Sponsors Baxter Healthcare SA, Thurgauer Str. 130, 8152 Glattpark (Opfikon), Switzerland Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Fresenius Medical Care AG & Co., KGaA, Else-Kröner-Straße 1, Bad Homburg, Germany Tel. +49 (0) Clinical outcomes in terms of patient survival have been progressively improving over the last 30 years. Fresenius Medical Care is committed to that improvement by continuously offering innovative state-of -the art PD systems, fluids, software and devices that assists physicians in the best possible care of their patients. With the Fresenius P 3 programme, we set new goals to peritoneal dialysis therapy, combining state-of-the-art devices, products and software into one comprehensive solution. The products in the P 3 programme complement each other, offering the highest quality of care and safety to PD patients. To inform the medical community of the conclusive evidence that we have made in PD, we rely on International and European experts meetings such as the EuroPD Meeting. This year, at EuroPD Meeting we are proud to share new discoveries and insights with the entire PD community aiming at improving patients quality of life and extend their time on PD. 20

23 11-14 October 2013 Maastricht, The Netherlands About Sanofi: Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. About Renvela/Renagel: Renvela and Renagel (sevelamer) are effective first-line monotherapies for controlling serum phosphorus in patients with chronic kidney disease (CKD). Renvela and Renagel are unlike other binders because they Do not contain calcium or metal, which can stay in the body Are not absorbed, so they do not accumulate in the body Sevelamer is available globally in over 82 countries. Depending on country, indication may vary. Should you need additional information, please contact Global PCS communications: sarah.connors@sanofi.com The 15th Congress of the international Society for Peritoneal Dialysis, taking place in Madrid, will feature an excellent and sophisticated scientific program that will serve an important platform for cutting edge developments in Peritoneal Dialysis. Visit our site and be informed about important dates and confirmed speakers that will be part of the conference. See you in Madrid! 21

24 EuroPD 2013 Final Programme Piet Mondrian, Molen: The Winkel Mill in Sunlight, Mondrian/Holtzman Trust c/o HCR International USA January 24,

25 11-14 October 2013 Maastricht, The Netherlands 23

26 EuroPD 2013 Final Programme 24

27 Europd Meeting Organisers In Conference Ltd Unit 1, Q Court Quality Street, Edinburgh EH4 5BP Tel: +44 (0) Fax: +44 (0) europd@in-conference.org.uk Web:

28 Peritoneal dialysis (PD) is associated with clinical benefi ts that can set up end stage renal disease (ESRD) patients for future success compared to conventional haemodialysis: Patients starting on PD are associated with initial short-term survival advantage 1,2 PD better preserves residual renal function 3* PD may offer a strong bridge to transplant 4,5 By starting your patients on PD, you will be preparing them for whatever ESRD sends their way. PD. Stronger than you think. Accepted for publication in JASN *Compared to HD using standard quality dialysis fluid. References: 1. Yeates K, Zhu N, Vonesh E, Trpeski L, Blake P, Fenton S. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. Nephrol Dial Transplant Sep;27(9): Mehrotra R, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med. 2011; 171: Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Predictors of the rate of decline of residual renal function in incident dialysis patients.kidney Int. 2002;62: Schwenger V, Dohler B, Morath C, Zeier M, Opelz G. The role of pretransplant dialysis modality on renal allograft outcome. Nephrol Dial Transplant. 2011;26: Molnar MZ, Mehrotra R, Duong U, et al. Dialysis modality and outcomes in kidney transplant recipients. Clin J Am Soc Nephrol. 2012;7: For more information, please contact your local Baxter representative: Baxter is a trademark of Baxter International Inc. RR-RD /2013